Coelho, T. Et Al. 2023. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. NEUROLOGY AND THERAPY , vol.12, no.1 , 267-287.

Coelho, T., Cruz, M. W., Chao, C., Parman, Y., Wixner, J., Weiler, M., ... Barroso, F. A.(2023). Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. NEUROLOGY AND THERAPY , vol.12, no.1, 267-287.

Coelho, Teresa Et Al. "Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen," NEUROLOGY AND THERAPY , vol.12, no.1, 267-287, 2023

Coelho, Teresa Et Al. "Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen." NEUROLOGY AND THERAPY , vol.12, no.1, pp.267-287, 2023

Coelho, T. Et Al. (2023) . "Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen." NEUROLOGY AND THERAPY , vol.12, no.1, pp.267-287.

@article{article, author={Teresa Coelho Et Al. }, title={Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen}, journal={NEUROLOGY AND THERAPY}, year=2023, pages={267-287} }